6LBA 177-Lu-Dotatate significantly improves progression-free survival in patients with midgut neuroendocrine tumours: Results of the phase III NETTER-1 trial. (September 2015) - Strosberg, J.; Wolin, E.; Chasen, B.; Kulke, M.; Bushnell, D.; Caplin, M.; Baum, R.P.; Mittra, E.; Hobday, T.; Hendifar, A.; Oberg, K.; Lopera Sierra, M.; et al.